Skip to Content

West Pharmaceutical Services Inc WST

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

West Has Record Quarter and Raises Guidance; We're Above Top-Line Consensus, but Shares Look Pricey

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Wide-moat West Pharmaceutical Services had a strong start to the year with organic growth of 31% and adjusted EPS growth of 103% in the first quarter. While management raised guidance and now expects over $2.63 billion of sales in 2021 (compared with $2.5 billion previously), our forecasts remain higher than guidance, and we are maintaining our $215 fair value estimate.

Read Full Analysis

Company Profile

Business Description

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (77% of 2020 sales) and contract-manufactured products (23%). It generates 55% of its revenue from international markets and 45% from the United States.

Contact
530 Herman O. West Drive
Exton, PA, 19341-0645
T +1 610 594-2900
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 9,200